Home
Clinical Trials
Open-label Safety Study in Ad...

Open-label Safety Study in Adults With ADHD

Last Updated: 2017-05-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

724 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-06-30

Study Completion Date

2016-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the long-term safety and tolerability of SEP 225289 in adult subjects with Attention Deficit Hyperactivity Disorder (ADHD)

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Dasotraline Adult ADHD Study

NCT02276209

Adult Attention Deficit Hyperactivity Disorder

COMPLETED PHASE3

Adult Attention Deficit Hyperactivity Disorder

NCT01692782

Adult Attention Deficit Hyperactivity Disorder

COMPLETED PHASE2

Dasotraline Pediatric Extension Study

NCT02457819

Attention Deficit Hyperactivity Disorder

COMPLETED PHASE3

Dasotraline Pediatric ADHD Study

NCT02428088

Attention Deficit Hyperactivity Disorder

COMPLETED PHASE2/PHASE3

A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.

NCT03231800

Attention-Deficit Hyperactivity Disorder (ADHD)

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To evaluate the long-term safety and tolerability of SEP 225289 in adult subjects with ADHD by the incidence of adverse events (AEs; or serious AEs), AEs (or SAEs) leading to discontinuation

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Adult Attention Deficit Hyperactivity Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dasotraline

Dasotraline 4 mg, 6 mg, 8 mg, flexibly dosed

Group Type EXPERIMENTAL

Dasotraline

Intervention Type DRUG

Dasotraline 4 mg, 6 mg, 8 mg, flexibly dosed, once daily

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dasotraline

Dasotraline 4 mg, 6 mg, 8 mg, flexibly dosed, once daily

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject meets DSM 5 criteria for a primary diagnosis of ADHD (inattentive, hyperactive, or combined presentation) established by a comprehensive psychiatric evaluation that reviews DSM 5 criteria. Diagnosis is confirmed by CAADID Part 2 with checklist for DSM 5.
* Subject has an ADHD RS IV with adult prompts score of ≥ 22 at screening and baseline.
* Subject has agreed to participate by providing written informed consent and is willing and able to comply with the protocol, in the opinion of the investigator.
* Subject is 18 to 55 years old, inclusive, at the time of informed consent.
* Subject is male or a non-pregnant, non lactating female.
* Female subjects must have a negative serum pregnancy test; females who are post menopausal (defined as at least 12 months of spontaneous amenorrhea) and those who have undergone hysterectomy or bilateral oophorectomy will be exempted from the pregnancy test.
* Female subjects of childbearing potential and male subjects with female partners of childbearing potential must agree to use an effective and medically acceptable form of birth control throughout the study period.
* Subject has a negative breath alcohol test and a negative urine drug screen (UDS) for any illicit drug at screening.
* Subject is judged by the investigator to be suitable for participation in a 12 month clinical trial involving open-label dasotraline treatment.
* Subject can read well enough to understand the informed consent form and other subject materials.

Exclusion Criteria

* Subject has a psychiatric disorder other than ADHD that has been the primary focus of treatment at any time during the 12 months prior to screening.
* Subject has a past history of, or current presentation consistent with, bipolar disorder (including bipolar I and bipolar II), schizophrenia, schizoaffective disorder, or any other psychotic disorder, or a personality disorder per DSM 5 criteria.
* Subject has a history of substance abuse or drug dependence (excluding nicotine and caffeine) within the 12 months prior to screening, as defined by the DSM 5 criteria.
* Subject has a history of epilepsy, seizures (except childhood febrile seizures), unexplained syncope or other unexplained blackouts (except single incident), or head trauma with loss of consciousness lasting more than 5 minutes.
* Subject has a currently active medical condition (other than ADHD) that, in the opinion of the investigator, could interfere with the ability of the subject to participate in the study.
* Subject is currently taking or has taken within the previous 6 months an anticonvulsant medication (eg, phenytoin, carbamazepine, lamotrigine, valproic acid, etc); antipsychotic medication; or lithium (any lithium preparation or formulation).
* Subject is currently taking an alpha 2 adrenergic receptor agonist (including clonidine and guanfacine), or serotonin-norepinephrine reuptake inhibitor (SNRI; eg, venlafaxine), or dopamine-norepinephrine reuptake inhibitor (DNRI; eg, bupropion), or monoamine oxidase \[MAO\] inhibitor. Note: Subjects who discontinue these medications and wash-out from them for a minimum of 7 days prior to the first dose of study drug will be allowed to enroll in the study.
* Subject is currently undergoing Cognitive Behavioral Therapy (CBT).
* Subject has a Body Mass Index (BMI) less than 18 or greater than 35 kg/m2 (see Appendix V).
* Subject answers "yes" to "Suicidal Ideation" item 4 (active suicidal ideation with some intent to act, without specific plan) or item 5 (active suicidal ideation with specific plan and intent) on the C SSRS assessment at screening (in the past month). Subjects who answer "yes" to this question must be referred to the investigator for follow up evaluation.
* Subject has attempted suicide within 1 year prior to the screening period.
* Subject has history of positive test for Hepatitis B surface antigen or Hepatitis C antibody and has liver function test results at screening above the upper limit of normal for the reference lab.
* Subject is known to have tested positive for human immunodeficiency virus (HIV).
* Subject has a clinically significant abnormality on screening evaluation including physical examination, vital signs, ECG, or laboratory tests that the investigator considers to be inappropriate to allow participation in the study.
* The subject's screening ECG shows a corrected QT interval using Fridericia's formula (QTcF) of ≥ 450 msec for male subjects or ≥ 470 msec for female subjects. Eligibility will be based on the core laboratory ECG interpretation report.
* The subject's screening serum chemistry results show an alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value ≥ 2 times the upper limit of normal (ULN), or a blood urea nitrogen (BUN) value ≥ 1.5 times the ULN for the reference laboratory.
* Subject is currently participating or has participated in a clinical trial within the last 90 days or has participated in more than 2 clinical trials within the past year. This includes studies using marketed compounds or devices.
* Subject has a history of allergic reaction or has a known or suspected sensitivity to any substance that is contained in the study drug formulation.
* Subject has previously been randomized in a clinical trial of dasotraline.
* Subject is likely to be noncompliant in the investigator's opinion.
* Subject is an investigational site staff member or the relative of an investigational site staff member.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

SEP289 Medical Director

Role: STUDY_DIRECTOR

Sumitomo Pharma America, Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Southern California Research LLC

Beverly Hills, California, United States

Site Status

Pharmacology Research Institute

Encino, California, United States

Site Status

Synergy Clinical Research of Escondido

Escondido, California, United States

Site Status

Collaborative Neuroscience Network, LLC

Garden Grove, California, United States

Site Status

Pharmacology Research Institute

Los Alamitos, California, United States

Site Status

Excell Research, Inc

Oceanside, California, United States

Site Status

Artemis Institute for Clinical Research

San Diego, California, United States

Site Status

MCB Clinical Research Centers, LLC

Colorado Springs, Colorado, United States

Site Status

Florida Clinical Research Center LLC

Bradenton, Florida, United States

Site Status

Gulfcoast Clinical Research

Fort Myers, Florida, United States

Site Status

Broward Research Group, Inc.

Hollywood, Florida, United States

Site Status

Clinical Neuroscience Solutions, Inc.

Jacksonville, Florida, United States

Site Status

Geroge M. Joseph MD, PA

Jacksonville Beach, Florida, United States

Site Status

Compass Research North, LLC

Leesburg, Florida, United States

Site Status

Florida Clinical Research Center, LLC

Maitland, Florida, United States

Site Status

Acumentality

Melbourne, Florida, United States

Site Status

Clinical Neuroscience Solutions, Inc

Orlando, Florida, United States

Site Status

Stedman Clinical Trials

Tampa, Florida, United States

Site Status

Institute for Advanced Medical Research

Alpharetta, Georgia, United States

Site Status

Atlanta Center for Medical Research

Atlanta, Georgia, United States

Site Status

iResearch Atlanta, LLC

Decatur, Georgia, United States

Site Status

Carman Research

Smyrna, Georgia, United States

Site Status

Goldpoint Clinical Research

Indianapolis, Indiana, United States

Site Status

Alpine Clinic

Lafayette, Indiana, United States

Site Status

Psychiatric Associates

Overland Park, Kansas, United States

Site Status

Lake Charles Clinical Trials LLC

Lake Charles, Louisiana, United States

Site Status

Kennedy Krieger Institute

Baltimore, Maryland, United States

Site Status

Massachusetts General Hospital

Boston, Massachusetts, United States

Site Status

Rochester Center for Behavioral Medicine

Rochester Hills, Michigan, United States

Site Status

Psychiatric Care & Research Center

O'Fallon, Missouri, United States

Site Status

Midwest Research Group

Saint Charles, Missouri, United States

Site Status

Premeir Psychiatric Research Institute, LLC

Lincoln, Nebraska, United States

Site Status

Center for Psychiatry and Behavioral Medicine, Inc.

Las Vegas, Nevada, United States

Site Status

Center for Emotional Fitness

Cherry Hill, New Jersey, United States

Site Status